Clinical trial Recruiting at 1 site Observational Women only

Safety study of avalglucosidase alfa during pregnancy

Official title: A Descriptive Safety Study Based on Data Collected From Women and Their Offspring Exposed to Nexviazyme/Nexviadyme (Avalglucosidase Alfa-ngpt/Avalglucosidase Alfa) During Pregnancy and/or Lactation in the Postmarketing Setting

Run by Sanofi · NCT05734521 · Data updated 2026-11-12

This study is looking at how safe the drug avalglucosidase alfa is for pregnant women and their babies during pregnancy and breastfeeding.

Quick facts

Study typeObservational
SexWomen only
Enrollment100 (estimated)
SponsorSanofi
Industry-sponsored
Locations1 site (Bridgewater, New Jersey)
StatusRecruiting
StartedOctober 26, 2022
Main results expectedOctober 31, 2032
Study endsOctober 31, 2032
Registry record updatedJanuary 16, 2026
Trial IDNCT05734521 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include women who have been exposed to avalglucosidase alfa during pregnancy or lactation and have consented to participate.

Probably not a fit

Patients who have not been exposed to avalglucosidase alfa during pregnancy or lactation may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect data on the safety of avalglucosidase alfa in women and their offspring during pregnancy and lactation. It will assess potential risks and complications associated with the drug for both mothers and their developing children. The study will follow participants for at least 10 years, evaluating outcomes in exposed infants, including their growth and development through the first year of life. Data will be gathered retrospectively and prospectively to provide a comprehensive understanding of the drug's effects.

Why it matters

Potential benefit: If successful, this study could provide critical safety information for pregnant women with Pompe disease using avalglucosidase alfa.

How similar studies have gone: While this study focuses on a specific population, similar observational studies have provided valuable safety data for other medications during pregnancy.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women and their offspring exposed to avalglucosidase alfa during pregnancy and/or lactation for whom an Individual Case Safety Report (ICSR) has been submitted to the Sanofi Global Pharmacovigilance (PV) department, and/or,
* Women exposed to avalglucosidase alfa during pregnancy and/or lactation who have provided informed consent to enroll in the Pompe Pregnancy Sub-registry.

Exclusion Criteria:

There are no exclusion criteria in this study.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Where it's running

  • Investigational site worldwide
    Bridgewater, New Jersey, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.